{
  "docId": "019dd923-622c-750b-8b97-5cb48bf2a635",
  "docSlug": "b8afd3741673",
  "documentTitle": "Chinook Therapeutics Inc (KDNY)",
  "authorId": "51_Muddy_Waters",
  "authorName": "Carson C. Block",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-05-16 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 16,
  "pageCount": 36,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 56,
  "notes": "The slide highlights discrepancies in reported clinical trial data, specifically regarding ESKD progression and adverse event reporting.",
  "elementsJson": [
    "paragraph",
    "data_table",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b97-5cb48bf2a635/16",
  "deckHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635#slide-16",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The FDA-reported numbers, which consolidate responders and non-responders, show something even stranger, in that they do not reflect the numbers given in either of the previously-consulted sources.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-25b7-709e-b8d0-b2c08cfaaf67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "adverse event frequency",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-25b7-709e-b8d0-b7d6e04afb8e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.72,
        "x": 0.14,
        "y": 0.71
      },
      "kind": "paragraph",
      "text": "The FDA-reported numbers, which consolidate responders and non-responders, show something even stranger, in that they do not reflect the numbers given in either of the previously-consulted sources:89",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "20c7113e-51cc-4e43-85a9-59c627fd5013",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.72,
        "x": 0.14,
        "y": 0.09
      },
      "kind": "paragraph",
      "text": "of the study is a numerical difference of 14 patients in the total number who progressed to end-stage kidney disease,87 this difference of four patients in the responder population is of interest, accounting for an effect close to 1/3 the size of the supposed ESKD effect. In other words, it meaningfully undermines the claim to renal benefit.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c4cc1aa-66b8-47cd-8d11-ad44a14a98f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.72,
        "x": 0.14,
        "y": 0.87
      },
      "kind": "source-note",
      "text": "87 https://repo.dma.dp.ua/6035/1/SONAR.pdf, Table 2. 88 “Supplementary Appendix” to the SONAR study. 89 https://clinicaltrials.gov/ct2/show/results/NCT01858532?term=atrasentan&draw=2&rank=4",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01a8b722-1338-49b4-be31-282cb77a344d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.72,
        "x": 0.14,
        "y": 0.64
      },
      "kind": "source-note",
      "text": "Data are derived from the safety population including 1321 patients in the atrasentan and 1320 patients in the placebo responder stratum and 508 patients in the atrasentan and 510 patients in the placebo non-responder stratum",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b50850f2-cbc4-4a57-810f-78e12be36aa6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.72,
        "x": 0.14,
        "y": 0.28
      },
      "kind": "table",
      "text": "Table showing adverse events for Responders (Atrasentan/Placebo) and Non-Responders (Atrasentan/Placebo).",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef7561c0-46fe-44dd-aeb3-685f14dffa84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.72,
        "x": 0.14,
        "y": 0.22
      },
      "kind": "title",
      "text": "Supplement table 4: Treatment emergent adverse events in “responders” and “non-responders”. Events with frequency >5% are reported.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e10ed2d6-f0c5-437f-922b-2417f2690149",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}